HK1217180A1 - 根據種核苷轉運載體的水平治療癌症的方法 - Google Patents

根據種核苷轉運載體的水平治療癌症的方法

Info

Publication number
HK1217180A1
HK1217180A1 HK16105218.7A HK16105218A HK1217180A1 HK 1217180 A1 HK1217180 A1 HK 1217180A1 HK 16105218 A HK16105218 A HK 16105218A HK 1217180 A1 HK1217180 A1 HK 1217180A1
Authority
HK
Hong Kong
Prior art keywords
level
treating cancer
cancer based
nucleoside transporter
nucleoside
Prior art date
Application number
HK16105218.7A
Other languages
English (en)
Inventor
Carla Heise
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of HK1217180A1 publication Critical patent/HK1217180A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
HK16105218.7A 2013-01-11 2016-05-06 根據種核苷轉運載體的水平治療癌症的方法 HK1217180A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361848780P 2013-01-11 2013-01-11
US201361752397P 2013-01-14 2013-01-14
US13/794,486 US20140199404A1 (en) 2013-01-11 2013-03-11 Method for treating cancer based on level of a nucleoside transporter
PCT/US2014/011006 WO2014110345A1 (en) 2013-01-11 2014-01-10 Method for treating cancer based on level of a nucleoside transporter

Publications (1)

Publication Number Publication Date
HK1217180A1 true HK1217180A1 (zh) 2016-12-30

Family

ID=51165318

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105218.7A HK1217180A1 (zh) 2013-01-11 2016-05-06 根據種核苷轉運載體的水平治療癌症的方法

Country Status (7)

Country Link
US (1) US20140199404A1 (zh)
EP (1) EP2943191A4 (zh)
JP (1) JP2016513075A (zh)
CA (1) CA2897673A1 (zh)
HK (1) HK1217180A1 (zh)
MX (1) MX2015008888A (zh)
WO (1) WO2014110345A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104587479A (zh) 2002-12-09 2015-05-06 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
PT1853250E (pt) 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN103054798B (zh) 2005-08-31 2021-03-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2155188B1 (en) * 2007-06-01 2013-10-09 Abraxis BioScience, LLC Methods and compositions for treating recurrent cancer
WO2010121000A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
MX364637B (es) 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
KR20200051841A (ko) 2011-04-28 2020-05-13 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
CN109771377A (zh) 2011-12-14 2019-05-21 阿布拉科斯生物科学有限公司 用于颗粒冻干或冷冻的聚合物赋形剂
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
KR102191311B1 (ko) 2013-03-12 2020-12-15 아브락시스 바이오사이언스, 엘엘씨 폐암의 치료 방법
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
KR102606071B1 (ko) 2015-06-29 2023-11-27 아브락시스 바이오사이언스, 엘엘씨 상피양 세포 종양을 치료하는 방법
WO2017095632A1 (en) * 2015-11-30 2017-06-08 Mayo Foundation For Medical Education And Research Heatr1 as a marker for chemoresistance
EP3522887A4 (en) * 2016-10-07 2020-06-10 Abraxis BioScience, LLC METHODS OF TREATING BILARIAN CANCER
CA3071612A1 (en) 2017-07-31 2019-02-07 January Therapeutics, Inc. Organophosphate derivatives
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
US11708637B2 (en) * 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
AU2020375810A1 (en) 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200204907B (en) * 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
PT1853250E (pt) * 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
CA2794147A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
EP2552453A2 (en) * 2010-03-30 2013-02-06 Clavis Pharma ASA Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
NZ604029A (en) * 2010-06-02 2015-07-31 Abraxis Bioscience Llc Methods of treating bladder cancer
US20130115628A1 (en) * 2011-08-02 2013-05-09 Ventana Medical Systems, Inc. Method for selection of chemotherapeutic agents for adenocarcinoma cancer

Also Published As

Publication number Publication date
EP2943191A4 (en) 2016-07-13
US20140199404A1 (en) 2014-07-17
CA2897673A1 (en) 2014-07-17
MX2015008888A (es) 2015-11-13
WO2014110345A1 (en) 2014-07-17
JP2016513075A (ja) 2016-05-12
EP2943191A1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
HK1217180A1 (zh) 根據種核苷轉運載體的水平治療癌症的方法
IL304252A (en) Cancer treatment methods
ZA201706616B (en) Method for treating cancer
IL289947A (en) A method for treating cancer
HK1217974A1 (zh) 處理動物基材的方法
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
HK1220155A1 (zh) 治療癌症的方法
SG11201603050TA (en) Methods for treating cancers
IL257691A (en) A method for treating cancer
HK1221381A1 (zh) 治療吞咽障礙的方法
IL231579B (en) Method for processing sar
AP2015008803A0 (en) Methods for treating psoriasis using an anti-il-23antibody
EP2968542A4 (en) BIOMARKERS FOR RADIOTHERAPY
EP2975633A4 (en) METHOD FOR PRODUCING A PATTERN
IL245037A0 (en) Treatment for pancreatic cancer
FI20135921A (fi) Menetelmä metallien käsittelemiseksi
GB201315846D0 (en) Method for treating or preventing hot flushes
EP2986120A4 (en) METHYLTRANSFERASE HEMMER FOR THE TREATMENT OF CANCER
PL3016682T3 (pl) Sposoby leczenia nowotworu
GB2535065B (en) Method for preprocessing metallic magnesium
EP2941270A4 (en) METHODS FOR TREATING INFLAMMATION
SG10201508795XA (en) Method for treating cancer
PT3055449T (pt) Processo para o tratamento de uma mistura
PT2836176T (pt) Técnica para tratar presbiopia
ZA201604162B (en) Method for treating sulfide-free minerals